Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.46 |
| ▸ | IKBKB | O14920 | 15/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12046621 | 0.93 | CCNA2 (0.51) | CCNA2CDK2CCNA1IKBKBPOLB | |
| SCHEMBL15850625 | 0.91 | CCNA2 (0.46) | CCNA2CDK2CCNA1IKBKBALDH1A1 | |
| SCHEMBL12046640 | 0.88 | ALDH1A1 (0.52) | CCNA2CDK2CCNA1IKBKBKDM4E | |
| SCHEMBL12046638 | 0.85 | ALDH1A1 (0.40) | IKBKBALDH1A1TP53HPGD | |
| SCHEMBL12046636 | 0.85 | CCNA2 (0.40) | CCNA2CDK2CCNA1IKBKBKDM4E | |
| SCHEMBL15850652 | 0.85 | CCNA2 (0.45) | CCNA2CDK2CCNA1ALDH1A1RAD52 | |
| SCHEMBL12060226 | 0.82 | KDM4E (0.39) | CCNA2CDK2CCNA1KDM4EALDH1A1 | |
| SCHEMBL12046639 | 0.82 | UGCG (0.38) | CCNA2CDK2CCNA1IKBKBALDH1A1 | |
| SCHEMBL12046654 | 0.81 | KMT2A (0.37) | CCNA2CDK2CCNA1KDM4EALDH1A1 | |
| SCHEMBL12046624 | 0.81 | ALDH1A1 (0.58) | CCNA2CDK2CCNA1IKBKBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071589-B2 | Dihydrobenzoindazoles | N. V. ORGANON (NL) | 2011-12-06 | — | — | US | disclosed |
| US-8071589-B2 | Dihydrobenzoindazoles | N. V. ORGANON (NL) | 2011-12-06 | — | — | US | disclosed |
| US-20110028451-A1 | Dihydrobenzoindazoles | N.V. ORGANON (NL) | 2011-02-03 | — | — | US | disclosed |
| US-20110028451-A1 | Dihydrobenzoindazoles | N.V. ORGANON (NL) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028451-A1 | Dihydrobenzoindazoles | DHODH, BRDT, HSD17B11 | CCNA2 4115/4885CDK2 2142/4885CCNA1 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.